BioBlog

This week, several advances in the oncology world brought new hope to patients suffering from lung and pancreatic cancer. Roche’s Tecentriq gained new first-line lung cancer use while a Roswell Park Team developed a two-pronged approach to pancreatic cancer that offers promise. Oncologists received

A two-combo cancer therapy has received FDA authorization for clinical researchers at a cancer center to begin a safety and effectiveness study. New data may have identified a genetic risk for lung cancer. The Trump Administration earmarked more money for states to conduct additional COVID-19

Many pharmaceutical companies are testing and repurposing older medications to battle COVID-19. The lengthy list includes beta-blockers, drugs to combat autoimmune diseases, and stem cell therapy. The FDA issued emergency clearance for Gilead’s remdesivir to be used in hospital patients with

In this week’s Innovation Partners BioBlog, we sum up the week’s news about the many changes the healthcare industry is undergoing during the COVID-19 pandemic. The drive to reopen the United States economy will start in pharmacies as more pledge to increase access to COVID-19 tests. Organizations

In this week’s edition of the Innovation Partners BioBlog, we focus on updates from the world of cancer treatments. Despite many companies halting tests and clinical trials due to the COVID-19 pandemic, a few are reporting clinical trial results and the FDA has approved a treatment for advanced

This edition of the Innovation Partners BioBlog looks at cancer care in the era of COVID-19. ASCO released guidelines to help hospitals apportion scarce resources among critically ill patients, including cancer patients, during the pandemic. A new approach to prostate cancer drugs may delay drug

On behalf of everyone at Innovation Partners, a Happy Passover Holiday and Happy Easter to all! We’re all struggling to navigate the “new normal” during this time of uncertainty, and the healthcare industry is no exception. Drug companies have delayed or stopped many new drug launches since

As the world continues to battle the novel coronavirus (COVID-19), drug companies, healthcare providers, and others are facing unprecedented challenges, too. Bristol-Myers-Squibb joins the list of companies halting introductions and clinical trials during the pandemic. Humana and Cigna waive